BMY: Technical and Fundamental AnalysisBMY: Technical and Fundamental Analysis
Two recent developments initiated a bearish movement in BMY last week:
News_1: Bristol-Myers Squibb's Melanoma Treatment Fails to Meet Primary Endpoint in Phase 3 Adjuvant Trial
Bristol-Myers Squibb said its Phase 3 trial evaluating opdualag for the adjuv